AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04122300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of placebo is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
Study NCT02284074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal LPS spray
Description: LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed. The dose per nostril corresponds to 1, 10, 30 and 100µg.
Study NCT02284074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Nasal LPS spray 1µg
Description: LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
Study NCT01893242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aleglitazar
Description: Aleglitazar 150 mcg oral doses, once a day for approximately 3 years
Study NCT01893242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to aleglitazar, once a day for approximately 3 years
Study NCT04039113 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study NCT04039113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT02740127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal Nerve Block (CNB)
Description: General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.
Study NCT02740127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.
Study NCT02740127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
Study NCT02740127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: Decadron 10 mg by bolus injection given by anesthesiologist in OR.
Study NCT02740127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.
Study NCT02740127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: General anesthesia given in the OR using Propofol titrated for induction.
Study NCT02740127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia given in the OR using Propofol titrated for induction.
Study NCT02740127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
Study NCT02740127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone Call
Description: Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
Study NCT01900990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation weaning
Description: We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
Study NCT03975348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow of warm and humidified oxygen/air mixture delivered through nasal cannula
Study NCT00751569 — intervention group
Intervention type: OTHER
Intervention: blood donation
Description: obtaining cord blood
Study NCT03378349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy
Description: The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
Study NCT03378349 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Consist of standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health, without the guidance of a psychologist or any CBT interventions.
Study NCT02009956 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Subjects receiving DESyne Novolimus Eluting CSS
Study NCT01484028 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A control lens (1DM)
Description: A marketed daily disposable contact lens
Study NCT01484028 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print and PVP for light eyes (EALE)
Description: A daily disposable contact lens
Study NCT02284074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Nasal LPS spray 10 µg
Description: LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
Study NCT02284074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Nasal LPS spray 30 µg
Description: LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
Study NCT02284074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Nasal LPS spray 100 µg
Description: LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
Study NCT05306002 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Antioxidant therapy
Description: Antioxidant therapy based in the following dietary components: Zinc, Selenium, Magnesium, carotenoids, indole-3-carbinol, curcumin, epigalactocatechin, caffeine, resveratrol, lycopene, genistein, phytoestrogens
Study NCT01484028 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A with print and PVP for dark eyes (EADE)
Description: A daily disposable contact lens
Study NCT02413697 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two-dimensional ultrasound
Description: Two-dimensional ultrasound guided embryo transfer
Study NCT02413697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three-dimensional ultrasound
Description: Three-dimensional ultrasound guided embryo transfer
Study NCT03579147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with BTL EMSCULPT device
Description: The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
Study NCT01140178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: Given IV
Study NCT01347723 — intervention group
Intervention type: OTHER
Intervention: scrambler therapy
Description: Undergo scrambler therapy
Study NCT01347723 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT05207319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated Moral Reasoning Development Intervention (MRDI)
Description: The MRDI is comprised of 4 components that are run concurrently: moral reasoning, strategies of anger management and problem-solving and social skills.
Study NCT03975348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Positive airway pressure applied through a sealed face mask
Study NCT03975348 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Facemask
Description: Oxygen therapy through a conventional facemask
Study NCT01159938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro
Description: Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
Study NCT03477448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: an antibiotic derived from Streptomyces verticillus, has an antitumor, antibacterial, and antiviral activity that may be related to its ability to bind with DNA, causing bleomycin strand scission and elimination of pyrimidine and purine bases. The bleomycin hydrolase enzyme, which is known to inactivate bleomycin, is normally found in all body tissues but is present in very small amounts in skin .~* Intra-lesional bleomycin injection (IBI) has been used for the treatment of warts.
Study NCT01967888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour
Study NCT01967888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiologic solution administered at 0.25 mL/kg/hour
Study NCT00408876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study NCT01347723 — intervention group
Intervention type: PROCEDURE
Intervention: management of therapy complications
Description: Undergo scrambler therapy
Study NCT00287040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored, interactive intervention for mammography screening
Description: Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings
Study NCT02538575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: a walk of 6 minutes repeated twice in an interval of 30 minutes
Study NCT04712162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Other
Description: Compare time to awakening and quality of recovery after general anesthesia between two groups.
Study NCT03055455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR imaging
Description: Conventional structural imaging will be combined with advanced neuroimaging modalities to evaluate integrity of white matter tracts, regional brain perfusion, and the 3-dimensional volume of specific brain structures.
Study NCT00408876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03500965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text-only PWL
Description: control condition (no image)
Study NCT03500965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: graphic PWL
Description: pictorial warning
Study NCT03500965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: absolute risk
Description: Percentage risk information for smoking-related diseases for smokers
Study NCT03500965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relative risk
Description: Percentage risk information for smoking-related diseases for smokers and non-smokers
Study NCT03477448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purified Protein Derivative
Description: is an extract of Mycobacterium tuberculosis and is used for testing exposure to tuberculin protein, either from a previous vaccination or from the environment. It contains live, attenuated Mycobacterium bovis.~* Using this protein derivative for immunotherapy of warts is important for two major aspects. First, because the obligatory immunization program in many developing countries - with high prevalence of wart in many of them - includes BCG vaccination. PPD has a high prevalence of immunity in the general population. Second, although immunotherapy is generally an inexpensive method of treatment in wart patients, PPD, among conventionally used antigens, is the cheapest
Study NCT01016860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17
Study NCT01016860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
Study NCT02561390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin prick test
Description: skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed
Study NCT02561390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific IgE measurement
Description: measure specific IgE of American cockroach, dog, cat, dust mite and mold
Study NCT03920436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: infrared water group
Description: This group takes 1,8 L of drinking water using a tumbler that emits far infrared rays at room temperature.
Study NCT03920436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: This group takes 1,8 L of drinking water using a tumbler at room temperature.
Study NCT03032497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG-based BCI analysis of fear avoidance
Description: Scalp EEG signals that are acquired and recorded from experiment 1 and 2 are analysed for healthy controls, participants with low back pain and participants with lower limb pain. Comparisons of signal patterns are made between groups. Assuming unique signal patterns are obtained for each groups, these signals are further analysed and used to develop a feedback brain training system to better manage pain and ideally reduce fear-avoidant behaviors towards pain.
Study NCT01288833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Close focus HD NBI Colonoscopy System
Description: Technically improved colonoscope with close focus high definition narrow band imaging. Optical specifications include a 2mm near field focal depth.
Study NCT03187080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline
Description: Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
Study NCT03187080 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline
Description: Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
Study NCT03187080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after breast surgery (ERABS) strategies
Description: For comparing ERABS strategies to current standard of care, the following perioperative strategies will be utilized:~* Standardized written information given preoperatively.~* Allow clear liquids for up to 2 hours prior to arrival at the surgery center.~* Use paravertebral block to augment postoperative pain control.~* Standardized multimodal analgesic regimen~* Antiemetics~* Easily accessible call-in or walk-in postop care/support~The proposed strategies differ from standard of care in the following ways:~* PVB is less commonly used in elective surgery.~* Patients do not eat or drink after midnight.~* There is no standardized preoperative information packet.~* Anesthetic/intraoperative analgesic and antiemetic regimen varies between providers.
Study NCT03187080 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham paravertebral block using saline
Description: Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of sterile saline will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
Study NCT03187080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paravertebral block using local anesthetic
Description: Use of local anesthetic (0.25% bupivacaine) that is \*NOT\* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
Study NCT02472977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulocuplumab
Study NCT02472977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Study NCT00072033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin and Docetaxel
Description: cisplatin and docetaxel chemo- and radiochemotherapy
Study NCT01555606 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Patients will not be administered any treatment as part of the study and will receive usual care. Patients will be evaluated for PROs by obtaining narratives and photographs.
Study NCT02926391 — intervention group
Intervention type: DEVICE
Intervention: UNiD 3D VBR
Description: Corpectomy of one or several vertebral body(ies) followed by vertebral body(ies) replacement and fusion
Study NCT02115737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Group
Study NCT02115737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation group treatment
Study NCT04663269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg PF Dexamethasone
Description: analgesic provided in the erector spinae block is 20mL of 0.5% Bupivicaine with 4mg of PF Dexamethasone
Study NCT04663269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Control Test
Description: Peritubal block - standard local analgesic administration
Study NCT04881890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diabetes Prevention Program
Description: LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits
Study NCT03028194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curettage
Description: Postpartum uterine curettage with a sharp curette # 14 or #16, immediately after delivery of the placenta.
Study NCT03028194 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No procedure after delivery of the placenta
Study NCT04672057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessment of gait parameters
Description: Gait parameters have been recourded with the use of BTS G-Walk Wireless Digital Walking Analysis System on a 10-meter smooth walking area.
Study NCT00863369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV